CD47 and neoplasm: Future studies are anticipated to adopt personalized and bespoke strategies tailored to individual tumors, aiming to enhance the coverage of DIPG or DMG antigens for more efficient targeting Additionally, EphA3-targeted CAR T cells could be used in combination with other immunomodulatory drugs, such as an anti-CD47 antibody that could address the immunosuppressive tumor microenvronment.43